Showing 2541-2550 of 4063 results for "".
- Opthea Phase 2b Trial Results of OPT-302 in Combination with Lucentis for Wet AMD Meets Primary Endpointhttps://modernod.com/news/opthea-phase-2b-trial-results-of-opt-302-in-combination-with-lucentis-for-wet-amd-meets-primary-endpoint/2481405/Opthea announced that the phase 2b study results of OPT-302, the company’s anti-VEGF-C/-D “trap” agent administered in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular degeneration (AMD), met the prespecified primary efficacy endpoint.
- Omeros Receives $200 Million Milestone Payment from Raynerhttps://modernod.com/news/omeros-receives-200-million-milestone-payment-from-rayner/2481391/Omeros announced that Rayner has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated December 1, 2021, pursuant to which Omeros sold its ophthalmology product Omidria to Rayner in December of 2021. Omeros received
- Endogena Therapeutics Receives FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-receives-fda-fast-track-designation-for-ea-2353-for-the-treatment-of-retinitis-pigmentosa/2481387/The FDA has granted Fast Track designation to Endogena Therapeutics' EA-2353 for the treatment of retinitis pigmentosa (RP). EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into
- CORE Names Its “Top 10 of 2022” Scientific Papershttps://modernod.com/news/core-names-its-top-10-of-2022-scientific-papers/2481351/Ahead of the first global eye care conference of the year, the Centre for Ocular Research & Education (CORE) has announced its “Top 10 of 2022” publications list, designating works of significant value to clinicians, researchers, educators, and manufacturers. The papers
- Aldeyra Therapeutics Submits NDA to FDA for ADX‑2191 for Treatment of Primary Vitreoretinal Lymphomahttps://modernod.com/news/aldeyra-therapeutics-submits-new-drug-application-to-fda-for-adx2191-for-treatment-of-primary-vitreoretinal-lymphoma-1/2481306/Aldeyra Therapeutics announced the submission of a new drug application (NDA) to the FDA for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.</
- Amgen to Buy Horizon Therapeutics in Deal Worth $27.8 Billionhttps://modernod.com/news/amgen-to-buy-horizon-therapeutics-in-deal-worth-278-billion/2481288/Amgen announced it is acquiring rare disease drug company Horizon Therapeutics, maker eye disease drugs Tepezza and Uplizna, in a deal valued at $27.8 billion. The company will pay $116.50 in cash per share, a premium of 19.7% to Horizon’s last closing price. Tepezza (teprotumumab
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/Nanodropper has launched its 2022 Give the Gift of Vision program, an effort to donate 1,000 Nanodropper Adaptors to at-need patients in the United States and its global nonprofit partners, aiming to deliver better access to vision-saving care in low resource settings in Africa, Haiti, and e
- iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norwayhttps://modernod.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/iSTAR Medical announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commerciall
- BTIG to Host Ophthalmology Day on November 29, 2022https://modernod.com/news/btig-to-host-ophthalmology-day-on-november-29-2022/2481261/Global financial services firm BTIG announced that "Ophthalmology Day at BTIG" will take place on November 29, 2022. The virtual, 1-day event will include thematic panel discussions, one-on-one meetings and company presentations. The event will be hosted by:
- Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481247/Azura Ophthalmics announced positive 3-month efficacy and safety results from its phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD). The trial met its co-primary endpoints of improvements in Meibomian Glands Yielding Liquid Secretion (MGYLS; number of open glands) and Oc